A significant advancement in the treatment of IgA nephropathy (IgAN) is on the horizon, with Roche announcing positive results from its Phase III IMAgINATION study for sefaxersen. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in proteinuria, a key indicator of kidney damage. This breakthrough positions sefaxersen as a potential new therapeutic option for patients suffering from this chronic autoimmune disease, while also intensifying the competitive landscape with Novartis, which recently secured FDA approval for its own IgAN drug, Fabhalta (iptacopan), targeting a similar pathway.
IgA nephropathy, also known as Berger’s disease, is a relentless autoimmune disorder characterized by the accumulation of immunoglobulin A (IgA) in the kidneys. This deposition triggers inflammation and damage, leading to a progressive decline in kidney function. For a significant portion of patients, this trajectory culminates in end-stage kidney disease (ESKD), necessitating lifelong dialysis or kidney transplantation. The emotional and physical toll on patients and their families is immense, marked by uncertainty and the constant threat of kidney failure.
The IMAgINATION study (NCT05797610) enrolled patients with primary IgA nephropathy and assessed the efficacy of sefaxersen compared to a placebo. The prespecified interim analysis, conducted at 37 weeks, revealed that sefaxersen achieved its primary endpoint: a statistically significant and clinically meaningful reduction in proteinuria, as measured by the 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria, the presence of excess protein in the urine, is a critical marker of glomerular damage and a strong predictor of long-term kidney health. A decrease in UPCR is highly correlated with the preservation of kidney function.
This encouraging outcome offers a much-needed beacon of hope for the IgAN community. Bonnie Schneider, director and co-founder of the IgA Nephropathy Foundation, articulated the profound impact of such developments: "For patients and families navigating IgAN, the prospect of kidney failure, dialysis, or transplantation creates overwhelming uncertainty. As someone who has advocated for this community for over two decades, positive results from the IMAgINATION study give us hope that emerging therapies could help preserve kidney function and transform the treatment landscape."
A Glimpse into the Study Design and Future Milestones
The IMAgINATION study is designed as a blinded trial, with the long-term evaluation of sefaxersen’s impact on kidney function continuing for two years. The secondary endpoint will focus on the change in estimated glomerular filtration rate (eGFR) at week 105, providing crucial data on the drug’s ability to slow or halt the progression of kidney disease.
Roche plans to present the interim data from the IMAgINATION study, which is a collaboration with Ionis, at an upcoming medical congress. This presentation will be accompanied by submissions to health authorities, aiming for accelerated approval based on the robust 37-week efficacy findings. The prospect of accelerated approval underscores the urgent unmet need in IgAN and the potential of sefaxersen to address it swiftly.
The Evolving Landscape of IgAN Treatment: A Competitive Arena
The approval of sefaxersen by Roche would introduce another significant player into an increasingly dynamic therapeutic landscape for IgAN. In July 2026, Novartis achieved a landmark victory with the US Food and Drug Administration (FDA) approval of Fabhalta (iptacopan) for adults with primary IgAN at risk of disease progression. This marked a pivotal moment, as Fabhalta became the first complement inhibitor to receive regulatory approval for IgAN.
Both sefaxersen and Fabhalta share a common therapeutic target: complement factor B. The complement system is a crucial part of the innate immune system, but its dysregulation can contribute to inflammatory and autoimmune diseases like IgAN. By targeting complement factor B, these novel therapies aim to interrupt the cascade of inflammation and damage within the kidneys.
Prior to these recent advancements, established therapies for IgAN included Calliditas Therapeutics’ Tarpeyo (budesonide) and Travere Therapeutics’ Filspari (sparsentan). While these treatments have offered some benefit, the advent of complement inhibitors like sefaxersen and Fabhalta represents a paradigm shift, offering a more targeted and potentially more effective approach to managing the disease.
Understanding the Mechanisms of Action: Differentiating the Therapies
While both sefaxersen and Fabhalta target complement factor B, their mechanisms of administration and action differ. Sefaxersen, a once-monthly subcutaneous injection, is designed for self-administration by patients. It operates by inhibiting the production of factor B at the messenger RNA (mRNA) level, effectively reducing its synthesis.
In contrast, Fabhalta is an orally administered, small molecule drug taken twice daily. It directly binds to and inhibits complement factor B, thereby blocking its activity. These differences in administration and specific mode of action may influence patient preference, adherence, and ultimately, clinical outcomes.
Broader Industry Momentum and Future Outlook
The progress of sefaxersen is not occurring in isolation. The pharmaceutical industry is witnessing a surge of innovation in IgAN research and development. Vertex Pharmaceuticals is also pursuing regulatory approval for its IgAN drug, povetacicept, following positive results from its Phase III RAINER trial (NCT06564142). Furthermore, Otsuka’s Voyxact (sibeprenlimab-szsi) recently received FDA approval in November 2025, further expanding the therapeutic options available to patients.
The growing pipeline of novel IgAN therapies, particularly those targeting the complement pathway, signals a transformative period for the management of this challenging disease. The competition between these pharmaceutical giants, including Roche and Novartis, is expected to drive further research, refine treatment protocols, and ultimately lead to improved outcomes for countless individuals affected by IgAN.
Addressing the Unmet Need: A Patient-Centric Perspective
The burden of IgAN extends far beyond the physiological damage to the kidneys. Patients often face a complex journey involving frequent medical appointments, the psychological impact of a chronic and progressive illness, and the financial strain of treatment and potential long-term care. The development of more effective and accessible therapies is therefore paramount.
The prospect of therapies that can be self-administered, such as sefaxersen, holds significant appeal for patients, potentially reducing the burden of regular clinic visits and improving quality of life. Similarly, oral medications like Fabhalta offer convenience and ease of use. The ultimate goal is to not only slow disease progression but also to improve the daily lives of patients and empower them to manage their condition more effectively.
The Significance of Proteinuria Reduction
The reduction in proteinuria observed in the IMAgINATION study is a critical finding with profound implications. Proteinuria is a direct consequence of damage to the glomeruli, the filtering units of the kidneys. When these structures are compromised, they leak protein into the urine. Elevated levels of proteinuria are a strong predictor of faster kidney function decline and an increased risk of progressing to ESKD.
Therefore, a significant reduction in UPCR, as demonstrated by sefaxersen, suggests that the drug is not only mitigating inflammation but also actively protecting the delicate kidney structures from further damage. This is precisely what patients and clinicians have been seeking – a way to halt or significantly slow the relentless progression of IgAN.
Expert Insights and the Road Ahead
The positive interim results of the IMAgINATION study are a testament to years of dedicated research and development. The collaboration between Roche and Ionis has yielded a promising candidate that could soon become a cornerstone of IgAN treatment. As the study progresses towards its 105-week endpoint, the focus will remain on assessing the long-term impact on eGFR, which is the ultimate measure of kidney function preservation.
The journey from clinical trial to widespread patient access is often complex, involving rigorous regulatory review and market access considerations. However, the urgency of the unmet need in IgAN and the promising efficacy data for sefaxersen suggest a potentially swift path to approval.
The competition with Novartis’s Fabhalta is likely to be intense, with both companies vying for market share and advocating for their respective treatment paradigms. This healthy competition, however, is ultimately beneficial for patients, as it spurs further innovation and drives down the cost of treatments over time.
In conclusion, the positive interim results from Roche’s IMAgINATION study for sefaxersen mark a significant milestone in the fight against IgA nephropathy. This development, coupled with the recent FDA approval of Novartis’s Fabhalta, heralds a new era of targeted therapies for this debilitating autoimmune disease. As the field continues to evolve with promising candidates from Vertex and Otsuka, the future of IgAN treatment appears brighter than ever, offering renewed hope for preserving kidney function and improving the lives of millions worldwide.
About the Author
